Table 6.

Panel expressions of combining at least two immunostains in endocervical and endometrial adenocarcinomas.

		ECA	EMMA	p-value
MUC1* & P16	MUC1+, P16-	0 (0%)	10 (100%)	0.001
	MUC1-, P16+	8 (100%)	0 (0%)
MUC1 & VIM	MUC1+, VIM+	1 (7.7%)	9 (69.2%)	0.004
	MUC1-, VIM-	12 (92.3%)	4 (30.8%)
MUC1 & ER	MUC1+, ER+	0 (0%)	13 (100%)	0.001
	MUC1-, ER-	9 (100%)	0 (0%)
MUC1 & PR	MUC1+, PR+	0 (0%)	12 (72.2%)	0.001
	MUC1-, PR-	9 (100%)	0 (27.8%)
P16 & VIM	P16-, VIM+	0 (0%)	7 (77.8%)	0.002
	P16+, VIM-	9 (100%)	2 (22.2%)
P16 & ER	P16-, ER+	1 (11.1%)	14 (93.3%)	0.001
	P16+, ER-	8 (88.9%)	1 (6.7%)
P16 & PR	P16-, PR+	2 (18.2%)	13 (92.9%)	0.001
	P16+, PR-	9 (81.8%)	1 (7.1%)
VIM & ER	VIM+, ER+	0 (0%)	9 (90%)	0.001
	VIM-, ER-	10 (100%)	1 (10%)
VIM & PR	VIM+, PR+	0 (0%)	8 (88.9%)	0.001
	VIM-, PR-	10 (100%)	1 (11.1%)
ER & PR	ER+, PR+	2 (16.7%)	15 (100%)	0.001
	ER-, PR-	10 (83.3%)	0 (0%)
MUC1, ER & PR	MUC1+, ER+, PR+	0 (0%)	11 (100%)	0.001
	MUC1-, ER-, PR-	8 (100%)	0 (0%)

ECA, endocervical adenocarcinoma; EMMA, endometrial mucinous adenocarcinoma. * Apical and cytoplasmic MUC1 expression.